Trending Now: Longevity and Anti-senescence Therapy Market Share, Growth, Demand, Trends, Region Wise Analysis of Top Players and Forecasts – Cole of…

Longevity and Anti-senescence TherapyMarket 2020: Inclusive Insight

Los Angeles, United States, May 2020:The report titled Global Longevity and Anti-senescence Therapy Market is one of the most comprehensive and important additions to Alexareports archive of market research studies. It offers detailed research and analysis of key aspects of the global Longevity and Anti-senescence Therapy market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Longevity and Anti-senescence Therapy market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Longevity and Anti-senescence Therapy market is carefully analyzed and researched about by the market analysts.

Longevity and Anti-senescence Therapy Market competition by top manufacturers/ Key player Profiled: CohBar, TA Sciences, Unity Biotechnology, AgeX TherapeuticsInc, PowerVision Inc.

Get PDF Sample Copy of the Report to understand the structure of the complete report:(Including Full TOC, List of Tables & Figures, Chart) : https://www.alexareports.com/report-sample/869763

Global Longevity and Anti-senescence Therapy Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2026. According to the latest report added to the online repository of Alexareports the Longevity and Anti-senescence Therapy market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2026.

Longevity and Anti-senescence Therapy Market Segment by Type covers: Hemolytic Drug Therapy, Gene Therapy, Immunotherapy, Other Stem Cell Therapies

Longevity and Anti-senescence Therapy Market Segment by Application covers:Hospital, Medical Service Institution, Drug and Device Sales

After reading the Longevity and Anti-senescence Therapy market report, readers get insight into:

*Major drivers and restraining factors, opportunities and challenges, and the competitive landscape*New, promising avenues in key regions*New revenue streams for all players in emerging markets*Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions*Demand and uptake patterns in key industries of the Longevity and Anti-senescence Therapy market*New research and development projects in new technologies in key regional markets*Changing revenue share and size of key product segments during the forecast period*Technologies and business models with disruptive potential

Based on region, the globalLongevity and Anti-senescence Therapy market has been segmented into Americas (North America ((the U.S. and Canada),) and Latin Americas), Europe (Western Europe (Germany, France, Italy, Spain, UK and Rest of Europe) and Eastern Europe), Asia Pacific (Japan, India, China, Australia & South Korea, and Rest of Asia Pacific), and Middle East & Africa (Saudi Arabia, UAE, Kuwait, Qatar, South Africa, and Rest of Middle East & Africa).

Key questions answered in the report:

What will the market growth rate of Longevity and Anti-senescence Therapy market?What are the key factors driving the global Longevity and Anti-senescence Therapy market size?Who are the key manufacturers in Longevity and Anti-senescence Therapy market space?What are the market opportunities, market risk and market overview of the Longevity and Anti-senescence Therapy market?What are sales, revenue, and price analysis of top manufacturers of Longevity and Anti-senescence Therapy market?Who are the distributors, traders, and dealers of Longevity and Anti-senescence Therapy market?What are the Longevity and Anti-senescence Therapy market opportunities and threats faced by the vendors in the global Longevity and Anti-senescence Therapy industries?What are sales, revenue, and price analysis by types and applications of Longevity and Anti-senescence Therapy market?What are sales, revenue, and price analysis by regions of Longevity and Anti-senescence Therapy industries?

GetExclusive discount on this report now at https://www.alexareports.com/check-discount/869763

Table of ContentsSection 1 Longevity and Anti-senescence Therapy Product DefinitionSection 2 Global Longevity and Anti-senescence Therapy Market Manufacturer Share and Market Overview2.1 Global Manufacturer Longevity and Anti-senescence Therapy Shipments2.2 Global Manufacturer Longevity and Anti-senescence Therapy Business Revenue2.3 Global Longevity and Anti-senescence Therapy Market Overview2.4 COVID-19 Impact on Longevity and Anti-senescence Therapy IndustrySection 3 Manufacturer Longevity and Anti-senescence Therapy Business Introduction3.1 CohBar Longevity and Anti-senescence Therapy Business Introduction3.1.1 CohBar Longevity and Anti-senescence Therapy Shipments, Price, Revenue and Gross profit 2014-20193.1.2 CohBar Longevity and Anti-senescence Therapy Business Distribution by Region3.1.3 CohBar Interview Record3.1.4 CohBar Longevity and Anti-senescence Therapy Business Profile3.1.5 CohBar Longevity and Anti-senescence Therapy Product Specification3.2 TA Sciences Longevity and Anti-senescence Therapy Business Introduction3.2.1 TA Sciences Longevity and Anti-senescence Therapy Shipments, Price, Revenue and Gross profit 2014-20193.2.2 TA Sciences Longevity and Anti-senescence Therapy Business Distribution by Region3.2.3 Interview Record3.2.4 TA Sciences Longevity and Anti-senescence Therapy Business Overview3.2.5 TA Sciences Longevity and Anti-senescence Therapy Product Specification3.3 Unity Biotechnology Longevity and Anti-senescence Therapy Business Introduction3.3.1 Unity Biotechnology Longevity and Anti-senescence Therapy Shipments, Price, Revenue and Gross profit 2014-20193.3.2 Unity Biotechnology Longevity and Anti-senescence Therapy Business Distribution by Region3.3.3 Interview Record3.3.4 Unity Biotechnology Longevity and Anti-senescence Therapy Business Overview3.3.5 Unity Biotechnology Longevity and Anti-senescence Therapy Product Specification3.4 AgeX TherapeuticsInc Longevity and Anti-senescence Therapy Business Introduction3.5 PowerVision Inc. Longevity and Anti-senescence Therapy Business IntroductionSection 4 Global Longevity and Anti-senescence Therapy Market Segmentation (Region Level)4.1 North America Country4.1.1 United States Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.1.2 Canada Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.2 South America Country4.2.1 South America Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.3 Asia Country4.3.1 China Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.3.2 Japan Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.3.3 India Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.3.4 Korea Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.4 Europe Country4.4.1 Germany Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.4.2 UK Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.4.3 France Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.4.4 Italy Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.4.5 Europe Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.5 Other Country and Region4.5.1 Middle East Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.5.2 Africa Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.5.3 GCC Longevity and Anti-senescence Therapy Market Size and Price Analysis 2014-20194.6 Global Longevity and Anti-senescence Therapy Market Segmentation (Region Level) Analysis 2014-20194.7 Global Longevity and Anti-senescence Therapy Market Segmentation (Region Level) AnalysisSection 5 Global Longevity and Anti-senescence Therapy Market Segmentation (Product Type Level)5.1 Global Longevity and Anti-senescence Therapy Market Segmentation (Product Type Level) Market Size 2014-20195.2 Different Longevity and Anti-senescence Therapy Product Type Price 2014-20195.3 Global Longevity and Anti-senescence Therapy Market Segmentation (Product Type Level) AnalysisSection 6 Global Longevity and Anti-senescence Therapy Market Segmentation (Industry Level)6.1 Global Longevity and Anti-senescence Therapy Market Segmentation (Industry Level) Market Size 2014-20196.2 Different Industry Price 2014-20196.3 Global Longevity and Anti-senescence Therapy Market Segmentation (Industry Level) AnalysisSection 7 Global Longevity and Anti-senescence Therapy Market Segmentation (Channel Level)7.1 Global Longevity and Anti-senescence Therapy Market Segmentation (Channel Level) Sales Volume and Share 2014-20197.2 Global Longevity and Anti-senescence Therapy Market Segmentation (Channel Level) AnalysisSection 8 Longevity and Anti-senescence Therapy Market Forecast 2019-20248.1 Longevity and Anti-senescence Therapy Segmentation Market Forecast (Region Level)8.2 Longevity and Anti-senescence Therapy Segmentation Market Forecast (Product Type Level)8.3 Longevity and Anti-senescence Therapy Segmentation Market Forecast (Industry Level)8.4 Longevity and Anti-senescence Therapy Segmentation Market Forecast (Channel Level)Section 9 Longevity and Anti-senescence Therapy Segmentation Product Type9.1 Hemolytic Drug Therapy Product Introduction9.2 Gene Therapy Product Introduction9.3 Immunotherapy Product Introduction9.4 Other Stem Cell Therapies Product IntroductionSection 10 Longevity and Anti-senescence Therapy Segmentation Industry10.1 Hospital Clients10.2 Medical Service Institution Clients10.3 Drug and Device Sales ClientsSection 11 Longevity and Anti-senescence Therapy Cost of Production Analysis11.1 Raw Material Cost Analysis11.2 Technology Cost Analysis11.3 Labor Cost Analysis11.4 Cost OverviewSection 12 Conclusion

Do Inquiry About The Report Here: https://www.alexareports.com/send-an-enquiry/869763

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing a decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPh no: +1-408-844-4624Email: [emailprotected]Site: https://www.alexareports.com

Go here to read the rest:
Trending Now: Longevity and Anti-senescence Therapy Market Share, Growth, Demand, Trends, Region Wise Analysis of Top Players and Forecasts - Cole of...

Osteonecrosis Treatment Market Investment Opportunities By 2020-2027 | Leading Key Players Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co…

Global Osteonecrosis Treatment Market has witnessed continuous growth in the past few years and is projected to grow even further during the forecast period (2020-2027). The research presents a complete assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical data, and statistically supported and industry-validated market data. This is the latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. It delivers important information to identify and analyze the market need, market growth, and competition.

This all-inclusive Osteonecrosis Treatment Market research report includes a detailed on these trends, share, size that can help the businesses operating in the industry to figure out the market and strategize for their business development accordingly. The research report analyses the growth, market size, key segments, industry share, application, and key drivers.

We Do Offer Sample of this report. Kindly go through the follow information in order to access sample copy.

Note- This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (Structure Of The Report)

Research methodology adopted by Coherent Market Insights

Request sample report @ https://www.coherentmarketinsights.com/insight/request-sample/1490

The major manufacturers covered in this report: Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd. Hospitals, clinics, universities,

Key players in the Osteonecrosis Treatment market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All measurement shares split, and breakdowns have been resolute using secondary sources and verified primary sources. The Osteonecrosis Treatment Market report begins with a basic overview of the industry lifecycle, definitions, classifications, applications, and industry chain structure, and all these together will help leading players understand the scope of the Market, what characteristics it offers, and how it will fulfill customers requirements.

Regional Analysis for Osteonecrosis Treatment Market:

For comprehensive understanding of market dynamics, the Global Osteonecrosis Treatment Market is analyzed across key geographies namely North America, Europe, China, Japan, Southeast Asia, India, Central & South America. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

What Osteonecrosis Treatment Market report offers:

The complete knowledge of the Osteonecrosis Treatment Market is based on the latest industry news, opportunities, and trends. The Osteonecrosis Treatment Market research report offers a clear insight into the influential factors that are expected to transform the global market in the near future. Both top-down and bottom-up approaches have been used to estimate and validate the market size of the Osteonecrosis Treatment market, to estimate the size of various other dependent submarkets in the overall market.

Remarkable Attributes of Osteonecrosis Treatment Market Report:

The Report Answers Following Questions:

Key Content of Chapters:

Part 1:Terminology Definition, Industry Chain, Industry Dynamics & Regulations and Global Market Overview

Part 2:Upstream (Raw Materials / Components) & Manufacturing (Procurement Methods & Channels and Cost), Major Regional Production Overview and Trade Flow

Part 3:Product Segment Overview and Market Status

Part 4:Application / End-User Segment Overview and Market Status

Part 5:Region Segment Overview and Market Status

Part 6:Product & Application Segment Production & Demand by Region

Part 7:Market Forecast by Product, Application & Region

Part 8:Company information, Products & Services and Business Operation (Sales, Cost, Margin, etc.)

Part 9:Market Competition and Environment for New Entrants

Part 10:Conclusion,In the end, the report makes some important proposals for a new project of Osteonecrosis Treatment Market before evaluating its feasibility. Overall, the report covers the sales volume, price, revenue, gross margin, historical growth, and future perspectives in the Osteonecrosis Treatment market. It offers facts related to the mergers, acquirement, partnerships, and joint venture activities widespread in the market.

All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

The PDF Research only provides Table of Contents (ToC), scope of the report and research framework of the report.

PDF Brochureof this Report:https://www.coherentmarketinsights.com/insight/request-pdf/1490

**Be Safe and Stay Home**

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts US:

Mr. ShahCoherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Email:[emailprotected]Phone: US +1-206-701-6702/UK +44-020 8133 4027

Read more:
Osteonecrosis Treatment Market Investment Opportunities By 2020-2027 | Leading Key Players Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co...

Stem Cells Industry 2020 Includes The Major Application Segments And Size In The Global Market To 2026 – 3rd Watch News

A detailed research study on the Stem Cells Market was recently published by IndustryGrowthInsights. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report puts together a concise analysis of the growth factors influencing the current business scenario across various regions. Significant information pertaining to the industry analysis size, share, application, and statistics are summed in the report in order to present an ensemble prediction. Additionally, this report encompasses an accurate competitive analysis of major market players and their strategies during the projection timeline.

The latest report on the Stem Cells Market consists of an analysis of this industry and its segments. As per the report, the market is estimated to gain significant returns and register substantial y-o-y growth during the forecast period.

Request a Sample Report of Stem Cells Market at: https://industrygrowthinsights.com/request-sample/?reportId=214556

According to the report, the study offers details regarding the valuable estimations of the market such as market size, sales capacity, and profit projections. The report documents factors such as drivers, restraints, and opportunities that impacts the remuneration of this market.

An Outline of the Major Key Points of the Stem Cells Market Report:

Ask for Discount on Stem Cells Market Report at: https://industrygrowthinsights.com/ask-for-discount/?reportId=214556

The Geographical Landscape of the Market Include:

Buy Your Exclusive PDF Copy Now @ https://industrygrowthinsights.com/checkout/?reportId=214556

Some of the Major Highlights of TOC Covers:Chapter 1: Executive Summary

Chapter 2: Methodology & Scope

Chapter 3: Market Insights

Chapter 4: Company Profiles

For More Information on this report, Request Inquiry At: https://industrygrowthinsights.com/enquiry-before-buying/?reportId=214556

About IndustryGrowthInsights:INDUSTRYGROWTHINSIGHTS has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://IndustryGrowthInsights.com

Link:
Stem Cells Industry 2020 Includes The Major Application Segments And Size In The Global Market To 2026 - 3rd Watch News

High-throughput intracellular biopsy of microRNAs for dissecting the temporal dynamics of cellular heterogeneity – Science Advances

Abstract

The capability to analyze small RNAs responsible for post-transcriptional regulation of genes expression is essential for characterizing cellular phenotypes. Here, we describe an intracellular biopsy technique (inCell-Biopsy) for fast, multiplexed, and highly sensitive profiling of microRNAs (miRNAs). The technique uses an array of diamond nanoneedles that are functionalized with size-dependent RNA binding proteins, working as fishing rods to directly pull miRNAs out of cytoplasm while keeping the cells alive, thus enabling quasi-single-cell miRNA analysis. Each nanoneedle works as a reaction chamber for parallel in situ amplification, visualization, and quantification of miRNAs as low as femtomolar, which is sufficient to detect miRNAs of a single-copy intracellular abundance with specificity to single-nucleotide variation. Using inCell-Biopsy, we analyze the temporal miRNA transcriptome over the differentiation of embryonic stem cells (ESCs). The combinatorial miRNA expression patterns derived by inCell-Biopsy identify emerging cell subpopulations differentiated from ESCs and reveal the dynamic evolution of cellular heterogeneity.

Embryonic stem cells (ESCs) are self-renewable and can differentiate into all types of cells in an adult organism. They are increasingly used in disease modeling, drug discovery, and regenerative medicine (13). More recently, the emergence of induced pluripotent stem cells (iPSCs) eludes the potential of patient-specific regeneration of damaged or diseased tissues (4, 5) and brings stem cellbased therapy to the forefront of the development of previously unidentified treatments for many diseases that are challenging for traditional methods. One of the issues for these efforts is the development of protocols to ensure directed differentiation of stem cells both in vitro and in vivo (6), which relies on the understanding and controlling of the cellular heterogeneity generated from stem cell differentiation and is critical for the clinical adoption of relevant therapeutic strategies (7).

MicroRNAs (miRNAs), a class of noncoding small RNAs, were reported to be involved in the regulation of self-renewal and differentiation of many stem cells (8). They regulate gene expression by binding to specific mRNA targets to promote mRNA degradation or translational inhibition. Many recent studies have shown a close relationship between miRNA transcriptome and cellular heterogeneity in different tissues (9, 10) or over stem cell differentiation (11, 12). However, in situ profiling of miRNAs in living cells is still challenging, hindering the adoption of miRNA as a therapeutic indicator in clinical practices (13). The trace amount of miRNAs in cytoplasm requires a profiling technique to be highly specific and sensitive (13, 14). A size selection step is typically required, following the isolation of total RNA from cellular homogenate (13, 15). Because of the short length of miRNAs, small primers are required in polymerase chain reaction (PCR) and often cause reduced priming efficiency, nonspecific hybridization, and, thus, erroneous results (14).

Among the tools for miRNA profiling, quantitative reverse transcription PCR (qRT-PCR) is the gold standard, but it is rather a validation instead of discovery tool. Deep sequencing resolves miRNA transcriptome with an extremely high throughput, but it is, however, disadvantaged by high cost, long turnover time, and complex data analysis (13). Both methods inherit similar issues from the required PCR process as mentioned above. Alternatively, microarray provides multiplexed miRNA analysis based on probe-target hybridization but has lower specificity and sensitivity (13, 14). All these commonly used techniques require isolation of RNA sample from cellular lysates, providing only average measurements of miRNAs for all cells. Consequently, important information about the heterogeneity of the cell populations would be missing and is only accessible by using single cellbased analytical techniques (16). Some in situ miRNA assay tools were recently reported by combining high-resolution microscopy with nanotechnology (17, 18), which are less quantitative and sometimes limited by toxicity issues.

Here, we describe an intracellular biopsy (inCell-Biopsy) technique for multiplexed in situ profiling of miRNAs in living cells. An array of diamond nanoneedles were functionalized with RNA binding protein (p19) and were used as fishing rods to directly pull multiple targeted miRNAs out of cell cytoplasm in a few minutes, leaving the cells alive. After the inCell-Biopsy operation, each nanoneedle then worked as a separated reaction plant for parallel in situ amplification, visualization, and quantification of miRNAs. The detection limit can reach as low as 1015 M, which is almost three orders of magnitude lower than the abundance of a single copy in a cell. Using inCell-Biopsy, we demonstrated multiplexed profiling of miRNAs in living cells and analyzed the temporal miRNA transcriptome over the differentiation of ESCs toward motor neurons, revealing the cellular heterogeneity and associated evolutionary dynamics of the differentiated cell populations based on miRNA expression.

The inCell-Biopsy technique is based on the continuous development of a molecular fishing system (19), which uses an array of diamond nanoneedles as fishing rods for minimum-invasive and reversible access of cytoplasmic regions of mammalian cells (Fig. 1A and movie S1). Specifically, for fishing miRNAs, a size-dependent RNA binding protein, p19, was cross-linked to functionalize the nanoneedles, working as the fishing hook to capture double-strand RNAs (dsRNAs) (Fig. 1A; more details in fig. S1). P19 can selectively bind to all dsRNAs of 20 to 22 base pairs (bp) (20, 21), which is a range covering almost all miRNAs in mammalian cells. As mature intracellular miRNAs are mostly single stranded (22), in this study, for each targeted miRNA, a bait RNA sequence was delivered to the cytoplasm to hybridize with the targets for p19 to capture. When the functionalized diamond nanoneedles are interfaced with live cells using a centrifugation facilitated procedure, the fishing rods can penetrate the cell membrane to access the cytoplasmic region via a temporary membrane disruption, which simultaneously facilitates the intracellular delivery of the bait RNAs (fig. S1) (19, 23). Upon the retrieval of the nanoneedles, the targeted miRNAs are isolated, leaving the cells alive (viability, 96.2 1.5%; means SD, n = 3).

(A) Schematic illustration of intracellular biopsy of miRNAs from live cells. (B) On-needle amplification of miRNA signals by hybridization chain reaction (HCR). (C) DNase-assisted multiple rounds of signal visualization. (D) Image processing and informatic approaches for miRNA transcriptome analysis.

After the inCell-Biopsy operation, a hybridization chain reaction (HCR) was performed on the nanoneedles to amplify the miRNAs. The HCR is featured by two single-strand DNAs (ssDNAs) with a stem-loop structure (hairpin 1 and 2), which can cyclically hybridize with each other if the stem part of one sequence is open (Fig. 1B) (24). For each miRNA target, the corresponding bait RNA contains the complementary sequence plus a small encoding overhang part at its 3 end, which binds to a small DNA sequence (initiator) to trigger the HCR (Fig. 1B). To enhance the detection sensitivity, one of the hairpins (hairpin 1) was fluorescently labeled and was quenched until its stem opening in the HCR. For multiplexing, the overhang part of the bait sequence was uniquely encoded for different miRNA targets, so that multiple miRNA targets can be visualized by different fluorophores (table S1). While the number of optically separable fluorophores may be limited (e.g., four channels), we implemented multiple rounds of HCR by removing the DNA hairpins after collecting the signals at the end of each round using deoxyribonuclease I (DNase I) enzyme, so that a new set of miRNAs could be examined to improve the analytical throughput of the inCell-Biopsy technique (Fig. 1C). Three rounds of HCR enabled us to examine 12 miRNAs after each biopsy. To enhance assay reliability, we dedicated one of the four channels to a reference miRNA (Fig. 1D), cel-miR-39, which does not exist in human or rodent cells and was artificially introduced to the cell cytoplasm, thus to eliminate potential systemic errors caused by experimental variations. The expression level of a targeted miRNA was indicated by the normalized fluorescence (with respect to the reference) acquired by confocal microscopy. While the nanoneedles could not be correlated to each cell with one-to-one mapping, the scattered signal from thousands of nanoneedles still retains the rich information about the cell population based on their miRNA expression (Fig. 1D).

To characterize the detection limit of our inCell-Biopsy technique, we first performed a mock experiment by profiling miRNAs from medium containing a premixed dsRNA (miR-34a and corresponding bait sequence) at different concentrations varying from 1016 to 1010 M. A nanoneedle chip was incubated in the solution and then rinsed before proceeding to further analysis. For every chip, signals from more than 1000 nanoneedles were collected and quantified (Fig. 2, A and B). Our results showed reliable differentiation of dsRNA of tested concentrations down to 1015 M (Fig. 2C). The overall profile of the fluorescence intensities was observed to positively associate with the miRNA concentrations (Fig. 2D), and the ratio of positive nanoneedles also exhibited an association with the miRNA concentration, roughly following the Langmuir isotherm model (Fig. 2E; also see note S1) (25). To test the detection specificity, we performed an assay to detect the synthetic let-7a miRNA over sequences with 1nucleotide (nt) mismatch (let-7c) or 2-nt mismatches (let-7b), and showed that the inCell-Biopsy technique is specific to single-nucleotide variation by successfully discriminating closely related miRNA sequences (Fig. 2F). The inCell-Biopsy was then implemented to detect miRNAs (let-7a or miR-34a) in cultured A549 cells (Fig. 2G). The two miRNAs were reported to express with different abundance in the cells: Let-7a is highly expressed, and miR-34a is of relatively low intracellular level (26). The nanoneedle chip was interfaced with A549 cells using a centrifugation-controlled method to initiate the intracellular biopsy (19, 23) and to deliver the two bait sequences to the intracellular domain. After a 15-min fishing reaction, the chip was retrieved from cells for analysis. For successful miRNA biopsy, the nanoneedles were identified to colocalize with the fluorescence signals from HCR amplification (Fig. 2H), which is significantly higher than different controls (Fig. 2, I and J; also see fig. S2A). The HCR amplification is especially useful in the detection of miRNAs of low intracellular abundance (e.g., miR-34a), which would otherwise be unobservable without the on-needle HCR amplification (fig. S2B).

(A) SEM image of the diamond nanoneedles; scale bar, 50 m. (B) Fluorescence images (top view) showing miRNA signals (red) on the nanoneedles (green); scale bar, 50 m. For (A) and (B), the boxed region is enlarged below; scale bars, 10 m. (C) Analysis of detection limit with violin plots showing the distribution of miRNA signals from all nanoneedles. *P < 0.005 by Kruskal-Wallis test. a.u., arbitrary units. (D) Relationship between miRNA concentration and fluorescence averaged from all nanoneedles. The red line indicates logarithmic fit (R2 = 0.99, P < 0.001 by F test). (E) Relationship between miRNA concentration and ratio of signal+ nanoneedles. The blue dashed line indicates a nonlinear fit by Langmuir isotherm model (R2 = 0.98, P < 0.001 in F test). (F) Analysis of detection specificity. NC, no target included. *P < 0.001 by ANOVA test. (G) Image of A549 cells after treatment; scale bar, 50 m. (H) Fluorescence visualization of miRNAs (red, let-7a or miR-34a) on the nanoneedles (green); scale bars, 10 m for three-dimensional and top view, 1 m for enlarged view. (I) Comparison of miRNA (let-7a or miR-34a) signals from different controls. (J) Ratio of signal+ nanoneedles for experiments with or without HCR amplification. For (D), (E), (I), and (J), n = 3; the error bar indicates SEM; *P < 0.001 by ANOVA test.

The capability to capture the dynamics of miRNA expression is extremely important for a profiling technique, as intracellular miRNAs play a key regulatory role in gene expression networks and change when cells switch their status (27). We then applied inCell-Biopsy to characterize relevant miRNAs in cells undergoing DNA damage or at different stages of a cell cycle to show its potential as a technique for probing cellular dynamics. Upon ultraviolet-induced DNA damage, let-7a was significantly down-regulated, and miR-16 and miR-26 were significantly up-regulated within just several minutes (fig. S3). In an extended temporal window as the cells progress to different division cycles, let-7a, miR-21, and miR-34a were observed to gradually increase from G1, to S, to G2 stage, while miR-24 remained stable at these stages (fig. S4). These results echo well with the literature (28, 29) and demonstrated inCell-Biopsys capability to monitor the fluctuation of miRNAs expression associated with cellular activity. In addition, the technique not only provides an overall assessment of miRNA expression in the cells but also captures the dynamic heterogeneity of cell populations, as confirmed by flow cytometry (fig. S4D) and qRT-PCR analysis (fig. S4, F and G).

After the above technical validations, we next applied inCell-Biopsy to investigate the temporal miRNA transcriptome and its relationship to cellular heterogeneity over the differentiation of mouse ESCs (mESCs) (HB9: GFP) toward motor neurons. We chose to profile nine different miRNAs in these cells at day 0, day 7, and day 14 from the induction of differentiation (Fig. 3, A and B). By using a custom-developed processing streamline and program (fig. S5), the expression of the nine miRNAs at various differentiation stages were obtained (Fig. 3C). When all the data were pooled together blindly, t-distributed stochastic neighbor embedding (t-SNE) (30) quantification showed the overall evolutionary change of the cells by the appearance of three self-organized clusters along with ESC differentiation, suggesting the validity of using combinatory miRNA expression pattern to indicate cell identity in this process (Fig. 3D).

(A) Experimental design of monitoring miRNA dynamics over the differentiation of embryonic stem cells (ESCs). RA, retinoic acid; and SAG, smoothened agonist. (B) Phase (Ph)contrast and fluorescence (green fluorescence indicates GFP) images showing morphological change of the cells along with differentiation. Scale bars, 50 m. (C) Confocal fluorescence image (top view) of diamond nanoneedles after fishing and HCR amplification. Scale bar, 20 m. The boxed region is enlarged below to show the expression of nine miRNAs from three rounds of amplification and visualization. Scale bars, 2 m. (D) t-SNE clustering of the pooled multidimensional miRNA vectors that resulted from inCell-biopsy at all three stages, showing the overall evolution of miRNA expression along with ESC differentiation.

Cells generated from ESC differentiation are typically heterogeneous (31), the inCell-Biopsy technique provides us the possibility to decipher this heterogeneity and biogenic evolution by using temporal miRNA dynamics (16). For each of the nine miRNA targets, we quantified its fold change at later differentiation stages with respect to the initial stem cell level, performed a self-diffusionbased spectral clustering (details in Materials and Methods Section) for the multidimensional miRNA measurements from thousands of nanoneedles pooled from six independent replicates, and determined the optimal numbers of clusters by eigengap (fig. S6A) (32). It was found that stable subpopulations were clearly observed at both 7 and 14 days after differentiation, and the cells appeared to be more scattered at the later stage (Fig. 4, A and B). The clustering results were also confirmed by t-SNE analysis (Fig. 4C) as well as principle component analysis (fig. S6B). The heatmaps and violin plots of the nine miRNAs showed the unique expression pattern of each cluster at a specific differentiation stage (Fig. 4, D, E, G, and H and fig. S7) and also suggested some similarities of particular clusters across different stages (e.g., cluster 3 at day 7 versus cluster 5 at day 14), implicating potential evolutionary correlation between them. Statistically, we were able to identify cluster-specific miRNA expression signatures (table S2). The shared signature between clusters of day 7 and day 14 supports our speculation of their evolutionary relationship. For instance, cluster 3 of day 7 and cluster 5 of day 14 shared the similar signature miRNAs of miR99a, miR218, and miR9. miR24, miR218, and miR219 are the shared signature miRNAs of cluster 4 of day 7 and cluster 3 of day 14. The discovery of these clusters was made by statistical analysis of signals from thousands of nanoneedles that were interfaced with a large population of cells. The proportion of a particular cluster (out of all nanoneedles) was also evaluated as an indicator for the percentage of a cell subpopulation, assuming an even distribution of the nanoneedles on a uniform culture of cells (Fig. 4F). This scattering information would be lost if averaged miRNA measurements were performed with cell lysate as what are mostly done by existing methods.

Self-diffusionbased spectral clustering and associated similarity network for the multidimensional miRNA measurements from thousands of nanoneedles at day 7 (A) or day 14 (B) of differentiation. (C) Separation of cellular subpopulations indicated by t-SNE analysis at day 7 or day 14. Heatmap showing distinct miRNA expression patterns between different clusters obtained from unsupervised classification at day 7 (D) or day 14 (E). (F) Sector graph showing the proportion of nanoneedles in each cluster out of the total number of nanoneedles on day 7 or day 14. Radar plots (left) and associated violin plots (right) show the averaged expression of the nine miRNAs for each of the identified clusters at day 7 (G) or day 14 (H).

To study the evolutionary correlation among different cell subpopulations (represented by the clusters) over differentiation, we used the multidimensional miRNA data from inCell-Biopsy to study the statistical association between the clusters of day 7 and day 14 to determine the closest pairs. Each cluster of day 14 can be uniquely traced back to link with a cluster of day 7 (P < 0.001, hypergeometric tests; Fig. 5A). For example, cluster 3/4/5 of day 14 was respectively found to be most correlated with cluster 4/2/3 of day 7; these paired clusters also showed similar miRNA expression patterns as shown in the violin plots (Fig. 4, G and H). Clusters 1 and 2 of day 14 both traced back to cluster 1 of day 7, suggesting cluster 2 of day 14 to be a newly differentiated subpopulation derived from cluster 1 of day 7 (Fig. 5B).

(A) Hypergeometric tests for determining the closest pair of clusters from the two differentiation stages. Significant associations are labeled by red squares, colored in proportion to log10(P value) (all P < 0.001). (B) The phylogenetic tree shows the evolutionary relationship among the clusters (cell subpopulations) as differentiation proceeds. The widths of the branches are proportionate to transformed P values [log10(P values)] derived from hypergeometric tests. (C) Correlation between the cluster miRNA pattern (derived from inCell-biopsy) with the results acquired by miR-seq for sorted motor neurons/progenitors. *P < 0.001. (D) Quantitative analysis of the averaged expression of the nine miRNAs for motor neuronlike clusters at day 7 and day 14. Error bars indicate SEM from six independent experiments. (E) Density histograms and associated violin plots showing the variation and distribution of nine miRNAs expression for motor neuronlike clusters at day 7 and day 14.

To figure out the relationship between the identified cluster based on miRNA expression and the cell type identity, we then focused on differentiated motor neuron/progenitors (GFP+) and compared the inCell-Biopsyacquired miRNA profile for each cluster to the data acquired by miRNA sequencing (miR-seq) for sorted motor neuron/progenitors at various differentiation stages. We found that the majority of the nine-dimensional miRNA vectors in cluster 3 of day 7 or cluster 5 of day 14 showed significantly higher correlation to the miR-seqmeasured miRNA expression pattern (P < 0.001, Wilcoxon signed-rank test; Fig. 5C), which was not observed for the other clusters of the same differentiation stage, suggesting that the nanoneedles in cluster 3 of day 7 or cluster 5 of day 14 mostly sampled motor neurons/progenitors in the miRNA biopsy operation. Taking a closer look at the two clusters, we further observed dynamic changes of different miRNAs (Fig. 5, D and E). For example, miR-294, a stem cellspecific miRNA (33), was significantly reduced from day 7 to day 14, whereas the motor neuronenriching miR-9 and miR-218 (34) were significantly increased over the same period (Fig. 5D). In addition, for the two motor neuron-like clusters, the miRNA expression was generally more scattered at day 14 (compared with day 7; Fig. 5E), which suggested an increased variation of the cell status as differentiation progresses.

Here, we develop a highly versatile and powerful technique, inCell-Biopsy, for in situmultiplexed profiling of miRNAs in living cells. The technique is capable of cherry picking targeted miRNAs from cell cytoplasm while leaving the samples intact afterward. For quantitative analysis of cellular RNAs, most of the existing techniques (e.g., qRT-PCR, microarray, RNA sequencing) started with RNA samples extracted from a population of cells and only provide an averaged measurement of the cell population (13, 14). InCell-Biopsy, on the other hand, isolates targeted miRNAs from a large number of individual cells within just a few minutes by using a diamond nanoneedlefacilitated molecular fishing system (19), and parallels in situ amplification, visualization, and quantification of miRNAs using each nanoneedle as a separated reaction chamber. In this way, our method not only detects averaged miRNA expression level but also captures the cellular heterogeneity of a cell population based on miRNA profiling, which is typically missed in other methods and only accessible using single-cell RNA sequencing (scRNA-seq) analysis (16). In this study, the density of the diamond nanoneedles was roughly controlled at ~5 nanoneedles per 10 by 10 m2 region. Although we cannot establish an exact one-to-one (or multiple-to-one) contacting map between the nanoneedles and each individual cell, the inCell-Biopsy technique enables a quasisingle-cell analysis to provide rich information for characterizing cell mixtures by using multidimensional miRNA profiles. As a proof of concept, we used the inCell-Biopsy technique to dissect cellular heterogeneity over the differentiation of ESCs and investigated the evolution of the cells with a dynamic temporal miRNA transcriptome analysis.

While the intracellular biopsy strategy has been previously reported (19, 3537), in this study, such a concept was further elaborated with specific biochemical design targeting multiple miRNAs, along with a complete framework for multiplexed in situ signal amplification, visualization, and quantification, which altogether are formulated as a quasisingle-cell miRNA profiling platform. Notably, the diamond nanoneedles are rigid enough to puncture cell membrane and remain ultraelastic at nanoscale to sustain the deformation without fracture during an inCell-biopsy operation (38). Although different nanostructures were recently developed as tools to isolate intracellular materials from living cells (3537) and may have the potential to be used for detecting miRNAs when combined with sequencing techniques, our inCell-biopsy technique stands out with a balanced combination of in situ capability, high throughput, ease of use, and independence of expensive equipment.

As one of the core merits, the inCell-Biopsy does not involve any cell lysis and RNA preparation procedures; therefore, the examined cells can be preserved for further longitudinal analysis. This feature also markedly simplifies the experimental operation, reduces the processing time, and provides the opportunity to quantitatively examine the temporal dynamics of miRNA expression for the same batch of cells receiving external stimuli or undergoing internal switch of cellular programs. It would be extremely useful when miRNA profiling is used as a characterization or quality control for cell-based therapeutic treatment (39). Meanwhile, the capability to directly fish miRNAs from the cytoplasm of an individual cell effectively bypasses the dilution of low-abundance miRNAs and prevents sample loss during cell lysing and RNA extraction procedures. Although only a single copy of miRNA is presented in a cell, the actual concentration for nanoneedle-assisted inCell-Biopsy would be around 1013 to 1012 M, which is well tolerated by the detection limit of the technique (1015 M).

Our inCell-Biopsy is based on an intracellular molecular fishing system, in which diamond nanoneedles are used as the fishing rod and RNA binding protein (p19) is used as the fishing hook, which specifically binds to dsRNA (not to ssRNA or dsDNA) in a size-dependent manner (20). For an inCell-Biopsy operation, the dsRNA complexes are formed by the hybridization between the targeted single-strand miRNA and a complementary bait sequence, which was thought to diffuse into cell cytosol via the nanopuncture-induced reversible membrane disruption (23). It is also possible that cytosolic materials could diffuse to cells outside, but this should not be an issue for the treated cells in this study, as the nanoneedles were tightly interfaced with the mobile lipid bilayer membrane (fig. S1), making it less likely for intracellular components (e.g., miRNAs) to leak out and be captured. Notably, intracellular pri-miRNAs or pre-miRNAs that lead to false positive in traditional PCR-based detections (13) would not interfere with our assay, because their structures would prohibit bait hybridization and subsequent binding to p19 proteins. The introduction of an encoded bait sequence for each miRNA target further enhances the specificity of the inCell-Biopsy technique. Practically, p19 can bind to all available dsRNAs of the right length, so that multiplexed detection (e.g., nine miRNAs in this study) can be easily implemented by effortless intracellular delivery of multiple bait sequences (20). Compared with scRNA-seq, the throughput of the inCell-Biopsy technique may be lower at the current stage, but it has, undoubtedly, advantages in substantially lower cost and more efficient experimental protocol. For improvement, the fluorescence labeling system can also be fine-tuned to include more channels to improve the assay throughput. For example, if the hairpin sequences were labeled with quantum dots, it would be easy to achieve an eight-channel imaging system, and three rounds of imaging would increase the throughput to 21 miRNA targets. In addition, the incorporation of certain barcoding strategy (e.g., nanostring system) (40) can further increase the analytical throughput to allow the analysis of hundreds of miRNA targets within a single visualization cycle.

As we had demonstrated, a nine-dimensional miRNA vector space produced by inCell-Biopsy already carries rich information for the identification of heterogeneous clusters that represent the cellular subpopulations differentiated from ESCs. The clustering was autonomously derived from a quasisingle-cell analysis of the miRNA expression patterns, which have recently been reported to be a good indicator for cellular heterogeneity (11, 12). While we cannot spatially determine the contacting relationship of each nanoneedle to an individual cell, statistically, the miRNA profiling by inCell-Biopsy can still reflect the compositional nature of examined cells, assuming a random but uniform distribution of the diamond nanoneedles over an evenly cultured cell. The multidimensional miRNA vector derived from each nanoneedle is treated as an input to a huge miRNA vector space, which effectively created a quasisingle-cell analysis framework for miRNA transcriptome analysis. Particularly, in this study, the correspondence between nanoneedle clusters and identity of specific cell subpopulation was verified to further confirm the validity of the analytical results acquired by inCell-Biopsy. For example, we used a protocol to direct motor neuron differentiation and blindly identified a major nanoneedle cluster (out of all nanoneedles) that was highly correlated to motor neuron identity at both day 7 and day after differentiation. However, when the same mESCs (HB9: GFP) were undergoing spontaneous differentiation without the induction compounds (retinoic acid and smoothened agonist), the motor neuron-like cluster was not discoverable (fig. S8).

The capability to retain cell sample after inCell-Biopsy operation enables multiround miRNA profiling at different time points, thus providing a temporal miRNA transcriptome analysis. Our results show that the inCell-Biopsy not only creates a quick snapshot of the heterogeneity of the examined live cells based on their miRNA profiles but also captures the temporal dynamics of miRNA expression, and it subsequently gives the cellular evolutionary path, as well as the biogenic relationship among heterogeneous emerging cell populations, which is especially informative for clinical applications (7).

In summary, we demonstrate a novel and powerful technique, inCell-Biopsy, for profiling miRNAs in living cells. The temporal miRNA dynamics captured by this technique can be used to reveal the evolution of cellular heterogeneity in mixed cell populations over extended culture periods, potentially providing a quick and convenient evaluation platform for the quality control of the emerging therapeutic strategies involving cell components.

HB9: GFP mESCs were acquired from the Stem Cell Core Facility of Columbia University. ESCs were seeded in a petri dish coated with 0.1% gelatin and were further cultured in an incubator at 37C with 5% CO2 for proliferation. After 3 days, ESCs were trypsinized for cell seeding. Typically, 250 ml of ESC culture medium consisted of 200 ml of EmbryoMax Dulbecco's modified Eagle's medium (DMEM) (Millipore), 37.5 ml of fetal bovine serum (FBS; Hyclone), 2.5 ml of EmbryoMax MEM Nonessential Amino Acids (Millipore), 2.5 ml of nucleosides (Millipore), 2.5 ml of 200 mM l-glutamine (Invitrogen), 2.5 ml of penicillin/streptomycin (pen/strep) (10,000 U/ml penicillin and 10,000 g/ml streptomycin, Invitrogen), 180 l of diluted 2-mercaptoethanol [diluted 1:100 in phosphate-buffered saline (PBS) with Mg and Ca; Invitrogen], and 25 l of leukemia inhibitory factor (LIF)/ESGRO (Millipore). Afterward, the embryonic stem medium was replaced by differentiation medium. Typically, 450 ml of differentiation medium consisted of 200 ml of Advanced DMEM/F12 (Invitrogen), 200 ml of Neurobasal Medium (Invitrogen), 46 ml of KnockOut Serum Replacement (Invitrogen), 4.6 ml of pen/strep, 4.6 ml of l-glutamine, and 320 l of diluted 2-mercaptoethanol. After 2 days, retinoic acid (RA; diluted 1:1000 in differentiation medium; Sigma-Aldrich) and smoothened agonist (SAG; dilutes 1:1000 in differentiation medium; Sigma-Aldrich) were added into the medium for a strong induction to motor neuron differentiation. After 3 days of in vitro differentiation, the differentiation medium supplemented with 4.5 l of glial-derived neurotrophic factor (Invitrogen), 9 ml of B27 (Invitrogen), and 4.5 ml of N2 supplement (Invitrogen) was used for a better motor neuron growth.

A549 cancer cells were maintained in DMEM (Life Technologies) supplemented with 10% FBS, l-glutamine, and pen/strep. Before molecular fishing experiments, cells were seeded in a four-well multidish (Nunclon) and allowed to grow until ~80% confluence.

The fabrication of diamond nanoneedles follows a protocol as previously described (19), involving the deposition of nanodiamond film and subsequent bias-assisted reactive ion etching (RIE) by electron cyclotron resonance microwave plasma chemical vapor deposition (ECR-MPCVD). N-type (001) silicon wafers of 3-inch diameter were used as a substrate. Before nanodiamond deposition, the substrate was soaked in ultrasonic bath for 60 min in ethanol, containing a suspension of nanodiamond powders with a grain size of 5 nm. Nanodiamond films 7 m thick were then deposited using a commercial ASTeX MPCVD equipped with a 1.5-kW microwave generator. The nanodiamond deposition was performed in the plasma induced in 10% CH4/H2 mixture at a total pressure of 30 torr and total gas flow rate of 200 standard cubic centimeter per minute (SCCM). The microwave power and deposition temperature were maintained at 1200 W and 800C, respectively. After the nanodiamond film deposition, RIE was performed using ECR-MPCVD. The ASTeX microwave source used a magnetic field of 875 G generated by an external magnetic coil. The RIE used a mixture of 45% Ar and 55% H2 as the reactive gases, which were supplied at a total flow rate of 20 SCCM. The substrate bias was 200 V, and the reactant pressure was 7 103 torr. The etching duration was 3 hours, and the input microwave power was 800 W. The morphology of the resulted diamond nanoneedles was characterized by scanning electron microscopy (SEM; Philips FEG SEM XL30), and the sample was tilted 90 for SEM.

To functionalize the diamond nanoneedles with p19 protein, a patch was first bathed in piranha (3:1, v/v; 98% H2SO4:27.5% H2O2) solution at 90C for 1.5 hours and then cleaned by distilled water, methanol, methanol/dichloride methane (DCM) mixture (3:1, v/v), and DCM sequentially. The nanoneedle patch was dried with nitrogen and then immersed in (3-aminopropyl)triethoxysilane solution (20% in DCM, v/v) overnight in a nitrogen-protected environment. Ethanol, isopropyl alcohol, and distilled water were sequentially used to rinse the nanoneedle patch, which would be further dried by nitrogen blow. The nanoneedle patch was then bathed in NHS-biotin solution (1 g/ml in PBS; Sigma-Aldrich) for 1 hour, streptavidin (20% of the streptavidin was labeled by fluorescent dye, Alexa Fluor 488) solution (10 g/ml in PBS; Invitrogen) for 2 hours, and biotinylated p19 siRNA binding protein solution (1 g/ml in PBS; New England Biolabs) for 1 hour. The nanoneedle patch was rinsed with distilled water between adjacent bath steps. After each experiment, the nanoneedle patch was soaked in hot (~90C) piranha solution (3:1, v/v; 98% H2SO4:27.5% H2O2) to remove all cross-linked materials (protein, nucleotides, etc.) on the nanoneedle surface, and SEM images were taken ensure the integrity of the nanoneedle structure. In this way, one patch can be used for at least 20 times. All the materials were acquired from Sigma-Aldrich unless otherwise specified.

Intracellular delivery of RNA bait sequences and miRNA fishing were performed using a centrifugation-controlled process (19). For cells in adherent culture, the medium was first removed, and 100 l of RNA bait sequence solution (10 nM for every bait sequence in serum-free medium) was applied to the cells. A nanoneedle patch was then placed facing toward the cells in a four-well petri dish. The whole complex was then placed in a centrifuge with a plate rotor and spun at 400 revolutions per minute (rpm) (22.8 g) for 4 min. After first centrifugation, the setup was placed in an incubator for 10 min to allow the bait sequences to diffuse into cytoplasm and to form dsRNA with their intracellular targets. Afterward, a second centrifugation was performed to enhance miRNA fishing results. During a centrifugation, the ramping speed was controlled to maintain a smooth acceleration to avoid any movement of the nanoneedle patch on cells. For acceleration and deceleration, 3 and 6 rpm/s were, respectively, selected.

Each RNA bait sequence used in the inCell-Biopsy has a unique 10-bp overhang sequence that can be used to amplify the signal coupling with the HCR (41). To perform the on-needle HCR amplification of miRNAs, the initiator sequences were diluted in the hybridization buffer containing 5 sodium citrate (SSC; Invitrogen) with 0.05% tween (pH 7.4; Invitrogen) to a final concentration of 10 nM; the hairpins were diluted in reaction buffer to a final work concentration of 20 nM. After a rinse with 0.05% SDS for 15 min, the nanoneedle patch was immersed in the initiator solution for hybridization between the dsRNAs and the initiator sequences. Following a quick rinse with the wash buffer (1 SSC, 0.05% tween), the patch was further incubated at 37C for 3 hours in hybridization buffer containing different hairpin DNAs (20 nM) with FAM, JOE, CY3, or CY5 fluorescent labels and black hole quencher. After the initiation of the HCR, the heterodimer was separated, and the absorption/emission of the fluorophore was restored. To guarantee the separation and reduce the requenching effect after the binding of hairpins 1 to 2, a short unmatched sequence was included in the hairpin sequences to work as a spacer. All hairpin and initiator oligonucleotides were acquired from BGI (Shenzhen, China) and summarized in table S1.

After first imaging, the HCR-amplified nanoneedle patch was immersed into DNase I solution for 1 hour in 37C to fully elute the DNA hybridized on the needle surface, followed by washing three times with wash buffer. After that, the nanoneedle patch was enabled to perform the HCR amplification to detect another four miRNA targets.

After each HCR amplification process, confocal microscopy (Leica SP8, 40 objective with 1.3 numerical aperture, water immersion) was performed to visualize and quantify the miRNAs captured on the surface of diamond nanoneedles. A nanoneedle patch was scanned with 0.3-m z resolution to get a stack of 45 to 55 slices, and both three-dimensional reconstruction and maximal projection of the stack were acquired. As a result of the HCR amplification, the fluorescent speckles (from DNA hairpin sequences) on nanoneedle surface was quantified and used to analyze the fishing of miRNA targets from the cells inside. After three rounds of amplification, images were projected and aligned to get a 12-channel image stack containing the fluorescence intensity and relative position information. To differentiate the positive signals from background noises or debris, fluorescent speckles of 0.4 to 1.5 m in diameter were firstly selected as nanoneedle regions, and a fluorescence threshold was then applied to sort out the positive nanoneedles with captured miRNAs. For each nanoneedle patch, we lastly obtained a matrix of intensities representing miRNA expression levels, where the columns are miRNA targets and the rows are different nanoneedles.

After obtaining the miRNA expression matrix, we divided the expression data of day 7 and day 14 by matched average value of that at embryo stem cell stage followed by log2 transformation to derive miRNA expression fold change data. To make sure that the miRNA expression data are comparable between different replicates, quantile normalization was subsequently performed for day 7 and day 14, respectively.

Having performed the preprocessing, the miRNA expression fold change data from all the replicates were combined as input for unsupervised classification at day 7 and day 14, respectively. We performed self-diffusion analysis (42), which was implemented by propagating the affinity matrices to improve sample similarities learning, followed by spectral clustering (32) for its relatively better adaptability to data distribution and the lower time consumption. We calculated eigengap (32) based on local scaling affinity, which infers the self-tuning affinity of sample-by-sample distances, and chose the optimal number (k) of clusters for clustering (fig. S6A). The sample-by-sample similarity matrices and similarity networks for day 7 and day 14 are shown in Fig. 4 (A and B), respectively.

For each miRNA profiling at day 7 (or day 14), we calculated Pearson correlation coefficients (PCCs) between its miRNA expression and the average expression levels of nanoneedles in different clusters at day 14 (or day 7). The nanoneedle at day 7 was subsequently assigned to the most correlated cluster at day 14 and vice versa. A confusion matrix was constructed to summarize the total number of nanoneedles classified simultaneously to each pair of clusters at day 7 and day 14, and a hypergeometric test was subsequently performed to evaluate the statistical significance of their association. First, we calculated the average expression profile of probes in each cluster of day 7. Second, for each nanoneedle in day 14, we calculated PCC with the average profile of each cluster of day 7, and the nanoneedle (day 14) was paired to the cluster (day 7) with the highest PCC. Third, all paired day 14day 7 nanoneedle relationships were counted, summarized, and followed by a hypergeometric test for overrepresentation of nanoneedles in day 14 paired to a cluster in day 7. Last, P values derived from the hypergeometric tests were adjusted for multiple hypothesis testing using the Benjamini-Hochberg procedure and illustrated as a heatmap. Similarly, using clusters of day 14 as a reference, we did association tests for the nanoneedles of day 7, and the conclusion is highly consistent.

To illustrate the potential evolutionary relationship between clusters at different stages, a phylogenetic tree was generated on the basis of the statistical associations between clusters at day 7 and day 14, where the branch width represents the transformed P value [log10(P)] derived from the hypergeometric tests. For validation, motor neuron cells (GFP+) were isolated with Sony SH800S cell sorter; the total RNA of sorted cells was extracted using the TRIzol reagent kit (Life Technologies) for miR-seq analysis (BGI). To investigate the potential cell type identities of nanoneedle clusters, we calculated PCCs between the inCell-Biopsyacquired miRNA profiles and the expression levels of the nine miRNAs measured by miR-seq.

To measure miRNAs (let-7a, miR-21, miR-24, miR-34a, and RNU43) using qRT-PCR, the total RNA was extracted from A549 cells using the TRIzol reagent kit (Life Technologies). For 15-l reactions, 10 ng of total RNA was reverse-transcribed and analyzed by the TaqMan miRNA Assays kit (product no. 4366596; Life Technologies). The expression of a particular miRNA was analyzed using the Applied Biosystems real-time PCR instrument following the manufacturers protocol.

At least three independent biological replicates were used for all experiments (n 3); for each replicate, signals from at least 250 nanoneedles were collected for analysis. For Fig. 2C, the bin size along the y axis was 60 (fluorescence, arbitrary units) for the violin plots; the whisker range of the overlaying boxplots is 1 to 99%, and each box shows 25, 50, and 75% percentile of the data. Kruskal-Wallis analysis was performed to determine the statistical significance among different dsRNA concentrations, and P < 0.005 indicates a significant difference. For Fig. 2 (H and I), analysis of variance (ANOVA) was performed to determine the statistical significance; P < 0.05 indicates a significant difference. The error bars indicate SEM from three independent experiments. For Fig. 4 (G and H), the bin size along the y axis was 0.1 (fold change of the expression level) for the violin plots. To identify cluster-specific miRNA expression signatures, a two-tailed Students t test was performed to assess whether each miRNA is differentially expressed between a specific cluster and the other clusters of day 7 (or day 14). For each cluster of day 7 (or day 14), the miRNA expression signatures were prioritized on the basis of the absolute log2 expression level (|log2EL| > = 0.75) and Benjamini-Hochbergadjusted P value (P < 0.001). For Fig. 5C, Wilcoxon signed-rank test was performed to determine the statistical significance; P < 0.001 indicates a significant difference. For Fig. 5D, the error bars indicate SEM from six independent experiments. For Fig. 5E, the bin size along the y axis was 0.1 (fold change of the expression level) for the violin plots.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license, which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.

Acknowledgments: Funding: This work was supported by the National Natural Science Foundation of China (81871452, 81802384, and 51772318), by the Science, Technology and Innovation Committee of Shenzhen Municipality (JCYJ20170818100342392, JCYJ20180507181624871, and JCYJ20170413141236903), by the General Research Fund (11278616, 11203017, 11102317, 11103718, and 11103619) from the Research Grants Council of Hong Kong SAR, and by the Health and Medical Research Fund (06172336) from the Food and Health Bureau of Hong Kong SAR. Author contributions: P.S. conceived the project, designed, and supervised the research. Z.W., X.Z., and K.X. carried out the experiments and analyzed the data. L.Q. and X.W. performed the statistical and bioinformatics analysis. Y.Y. and W.Z. provided the diamond nanoneedle array. M.L., E.H.C.C., X.J., and L.H. helped with the experiments. All authors contributed to the writing of the manuscript. Competing interests: P.S., W.Z., L.H., X.W., and Z.W. are inventors on a pending patent related to this work (no. US15/875,385, filed 18 January 2018). The authors declare that they have no competing interests. Data materials and availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.

Read the original post:
High-throughput intracellular biopsy of microRNAs for dissecting the temporal dynamics of cellular heterogeneity - Science Advances

BrainStorm to Present at the Raymond James Human Health Innovations Conference – PRNewswire

NEW YORK, June 11, 2020 /PRNewswire/ --BrainStorm Cell Therapeutics Inc.(NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Chaim Lebovits, CEO and Ralph Kern, MD, MHSc, President and Chief Medical Officer, will present a corporate overview on Thursday, June 18 at 9:00 am EST, during theRaymond James Human Health Innovations Conference, a virtual event connecting institutional investors with company management teams that will be held June 15-18, 2020.

Mr. Lebovits and Dr. Kern will update conference participants on the Company's investigational therapeutic, NurOwn, that is currently in a fully enrolled phase 3 study for the treatment of ALS and a phase 2 study for the treatment of progressive multiple sclerosis. Additionally, they will present an overview of the Company's financial position and pipeline. After the presentation, the management team will participate in a question and answer session with institutional investors.

Mr. Lebovits and Dr. Kern will be joined by David Setboun, PhD, MBA, Chief Operating Officer, Stacy Lindborg, PhD, Head of Global Clinical Research, and Preetam Shah, PhD, MBA, Chief Financial Officer, for a series of one-on-one meetings, with select institutional investors arranged by Raymond James.

Participants can view the presentation via the event link and those unable to join will have access to an archived link on the Company's Events and Presentation webpage after the conclusion of the conference.

EVENT: Raymond James Human Health Innovations Conference

PRESENTATION: Thursday, June 18th at 9:00 am EST

LINK: https://bit.ly/2YmZf8u

About NurOwn

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently receivedU.S.FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began inMarch 2019.

AboutBrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at sixU.S.sites supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a filing forU.S.FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently receivedU.S.FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment inMarch 2019.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: +1-862-397-1860[emailprotected]

Media:

Sean LeousWestwicke/ICR PRPhone: +1-646-677-1839[emailprotected]

SOURCE Brainstorm Cell Therapeutics Inc

More here:
BrainStorm to Present at the Raymond James Human Health Innovations Conference - PRNewswire

Stem Cell Assay Market Report 2020 by Global Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19…

Stem Cell Assay market report 2020 entitles with an in-depth analysis towards the competitive market, which involves the market shares and company outline of the major competitors functioning in the Stem Cell Assay market. The study offers detailed summarization of products, various technologies applied in the Stem Cell Assay type of product, and manufacturing analysis taking in to account all the major factors that include cost, revenue, gross profit and so on. This Stem Cell Assay report consists of a financial overview, market synopsis, demand towards various segments and growth aspects. Numerous applications, and analysis on demand and supply activities, Stem Cell Assay market price during the projected period. The global Stem Cell Assay market report will be maintaining good productivity with increasing CAGR of XX%. Considering all the basic aspects such as product type, Stem Cell Assay application, various industrial competitors, and regional analysis.

Request for a sample report here https://www.orbisresearch.com/contacts/request-sample/4718175

Prominent players included in the global Stem Cell Assay market:

Bio-Techne CorporationBio-Rad LaboratoriesPromega CorporationMerck KGaAHemogenixGE HealthcareCellular Dynamics InternationalSTEMCELL TechnologiesCell BiolabsThermo Fisher Scientific

The global Stem Cell Assay market division by product type:

Viability/CytotoxicityIsolation & PurificationCell IdentificationProliferationDifferentiationFunctionApoptosis

The global Stem Cell Assay market division by application:

Regenerative Medicine & Therapy DevelopmentDrug Discovery and DevelopmentClinical Research

Market bifurcation by Stem Cell Assay geographical region includes North America, Europe, Latin America, Middle East and Africa, Asia-Pacific, and Rest of the world. respectively.

The Stem Cell Assay report represents an important tool towards the manufacturers all over the world along with the value chain and also for new competitors by allowing them to benefit from business opportunities as well advanced business tactics. It has studied the Stem Cell Assay market thoroughly focusing on market size, growth opportunities, and market status.

Detailed qualitative Stem Cell Assay research approach which involves investigation and recognition of the following terms:

* Stem Cell Assay market classification

* Driving factors influencing Stem Cell Assay growth

* Stem Cell Assay key restraints and market opportunities

* Upcoming product developments and Stem Cell Assay major challenges

* SWOT (Strength, Weakness, Opportunities, and Threat) and Stem Cell Assay PORTERS Five Forces analysis

The Stem Cell Assay market report serves major analytics on the market position of the Stem Cell Assay industries and acts a valuable source for guiding and directing the companies interested in the Stem Cell Assay market as well individuals. The Stem Cell Assay market report explains the basic fundamentals related to the market strategies their applications, product specifications, definitions, various classifications, production process, their cost structure, Stem Cell Assay raw materials analysis and even more.

Ask our Expert if You Have a Query at: https://www.orbisresearch.com/contacts/enquiry-before-buying/4718175

Questions answered in the global Stem Cell Assay market report:

1. What are the market strategies applicable, market insight, and Stem Cell Assay product type analysis?

2. What are driving factors influencing the growth of the global Stem Cell Assay market, analysis by region and application?

3. What are the market dynamics, that involves the scope of the product and price breakdown of Stem Cell Assay key manufacturers?

4. Who are the major challenges, opportunities and risk factors for Stem Cell Assay market, including the upstream and downstream towards raw material and buyers?

5. Who are the key market players, Stem Cell Assay business outline by application, product type, market share and gross profit?

6. What are major threats tackled by the sellers in the global Stem Cell Assay market?

The Stem Cell Assay current and past data related to market signifies the existing market valuation and the future prospects. Moreover, data collected here are through primary and secondary research, that includes interviews with major Stem Cell Assay industries including the values of top manufacturers, their suppliers, and various application, as well company report, latest trends, and reviews. Also, through different research findings, Stem Cell Assay distribution channels, traders, results, and Appendix.

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Direct Purchase Report @ https://www.orbisresearch.com/contact/purchase-single-user/4718175

Follow this link:
Stem Cell Assay Market Report 2020 by Global Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19...

Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development – BioSpace

CARMIEL,Israel, June 8, 2020 /PRNewswire/ -- Protalix Biotherapeutics, Inc., (NYSE American: PLX) (TASE: PLX) today announced the appointment of Yael Hayon, Ph.D. as the Company's new Vice President, Research and Development, effective July5, 2020. On June 2, 2020, Yoseph Shaaltiel, Ph.D. retired from his position as the Company's Executive Vice President, Research and Development, effective June 15, 2020.

"Yossi's incredible scientific and entrepreneurial vision led to his founding of Protalix," said Zeev Bronfeld, Chairman of Protalix's Board of Directors. "Yossi's efforts resulted in the development of ProCellEx, our proprietary plant cell-based protein expression system which we use to produce taliglucerase alfa, an approved treatment for Gaucher disease, pegunigalsidase alfa, our investigationaltreatment for Fabry disease which is in the latter stages of clinical development and our other investigationaldrug candidates. The Board of Directors and I are immensely grateful to Yossi for his knowledge, leadership, integrity and professionalism in building Protalix from its founding days to where it is today. We wish him all the best in his future endeavors."

"I am delighted that Yael is joining the Protalix team where she will bring valuable and diverse research& development experience and knowledge," said Dror Bashan, Protalix's President and Chief Executive Officer. "We are greatly thankful to Yossi for his exceptional efforts in founding and building Protalix, and wish him great success in the future."

Dr. Hayon brings to the Company over a decade of experience in pharmaceutical researchand development, both in the scientific operations and the administrative functions. She most recently served as Vice President of Clinical Affairs of Syqe Medical Ltd., Tel-Aviv, where she, among other things, established the clinical and medical global strategy, and was responsible for providing strategic input on the regulatory development plan. Prior to her role at Syqe Medical, Dr. Hayon served as the Head of R&D Israeli Site of LogicBio Therapeutics, Inc., Cambridge, Massachusetts, where she managed LogicBio's Israeli-based Research and Development facility and was involved in strategic decision-making. From 2014 through 2016 she served as the R&D Manager, Stem Cell Medicine Ltd., Jerusalem, Israel. Dr. Hayon holds a Ph.D. in Neurobiology/Hematology, and an MS.c. in Neurobiology, both from the Hebrew University Faculty of Medicine, Jerusalem, Israel.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S.Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.

Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.

Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified version of the recombinant human GalactosidaseA protein for the proposed treatment of Fabry disease; OPRX106, an orally-delivered anti-inflammatory treatment; alidornase alfa for the treatment of Cystic Fibrosis; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms "expect," "anticipate," "believe," "estimate," "project," "plan," "should" and "intend," and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: that the FDA might not grant marketing approval for PRX102 in the currently anticipated timeline or at all and, if approved, whether PRX102 will be commercially successful; failure or delay in the commencement or completion of our preclinical and clinical trials; risks associated with the novel coronavirus disease (COVID19) outbreak, which may adversely impact our business, preclinical studies and clinical trials; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions; and other factors described in our filings with the U.S.Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.

Investor ContactChuck Padala, Managing DirectorLifeSci Advisors+1-646-627-8390chuck@lifesciadvisors.com

Media ContactBrian PinkstonLaVoieHealthScience+1-857-588-3347bpinkston@lavoiehealthscience.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/protalix-biotherapeutics-appoints-yael-hayon-phd-as-its-new-vice-president-research-and-development-301072291.html

SOURCE Protalix BioTherapeutics, Inc.

Visit link:
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development - BioSpace

Nick Cordero’s Wife Says He Had A ‘Rocky Night’ After His Fever Spiked – iHeartRadio

Despite hoping for a week of good news, Nick Cordero's wife Amanda Kloots revealed that the star experienced a "little blip" in his recovery from his COVID-19 complications.

On Tuesday (June 9), the fitness trainer took to Instagram Stories to reveal that her Broadway-starring husband "had a little bit of a rocky night last night" and "spiked a fever." Doctors had to intervene with medication and that seemed to do the trick for now. "They had to do a little bit of fixing of that and antibiotics," she explained. "Luckily, everything is back to normal today and that was just a little blip that can happen in ICU. I mean, anything can happen in ICU, but just a little blip but we're back to normal."

"Things are going, I think, good," Kloots continued, adding that doctors might perform another stem cell procedure to repair his lungs. "He's stable and they'll probably be looking at doing another, hopefully, CT scan of his lungs to see what kind of progress or if there's further damage in his lungs."

Coincidentally, Wednesday marks the first birthday for their child, Elvis Eduardo. "It breaks my heart that Nick can't be there," she confessed. "I literally can't even talk about it because it makes me so sad. I plan on FaceTiming so he can see Elvis," she said of the emotional day ahead of her. "I think it's going to be really hard. But luckily, I have my family and we're doing a nice family birthday party for Elvis, and we're going to try to make it as special as he can for the little guy."

In late May, Cordero faced a setback with his health, but Kloots admitted that despite the new lung infection, he was slowly recovering. The star has been hospitalized since March and had his leg amputated due to complications from the respiratory virus. He was placed in a medically-induced coma after surgery and woke up just a couple of weeks ago. Last week, it was revealed that Cordero was starting stem cell treatment to help his recovery. Doctors also suggested that Kloots bid farewell to him.

Read the original here:
Nick Cordero's Wife Says He Had A 'Rocky Night' After His Fever Spiked - iHeartRadio

Could these senolytic drugs halt the spread of COVID-19? – Health Europa

Professor Michael P Lisanti, Chair in Translational Medicine at the University of Salford, has been an active research scientist for more than 30 years and is an expert in the field of cellular senescence. He tells HEQ about the potential of readily available, low cost, MHRA- and FDA-approved drugs to possibly treat and prevent the spread of COVID-19.

Senolytic drugs can be used to prevent or reverse ageing. There have been studies in mice that have shown that if you use a genetic trick, you can reverse ageing-associated disease characteristics but the problem is you cant do that in humans, so you would need a drug. We set out to identify drugs that would selectively kill senescent cells, but not harm normal cells; for this purpose, we developed a drug screen where we looked at various agents which prohibit cancer stem cell activity and we came across azithromycin, which selectively killed senescent cells with efficiency of nearly 97% and did not harm the normal cells. When we looked at the literature, we saw that patients with cystic fibrosis had been treated with azithromycin cystic fibrosis is similar to accelerated ageing as a disease, because theres a huge amount of inflammation and fibrosis and it dramatically increased their lifespan and their survival rates.

Fibrosis is normally an ageing-associated disease characteristic: its what kills patients with cystic fibrosis, because their lungs become stiff and can no longer expand and contract, in order to breathe. The azithromycin was also behaving as an antifibrotic, removing or preventing the formation of senescent myofibroblast cells; so we actually had proof In previous studies that our drug was actually a senolytic. If you reread the literature with senolytic glasses, you realise that the proof of its efficacy in humans is already there.

Another study in Japan looked at azithromycin based on its activity in cystic fibrosis patients and then applied these finding to patients with idiopathic pulmonary fibrosis. The control group survival rate in that paper was 25%, but on azithromycin it was nearly 80%. There is evidence in the published literature that its either preventing or removing fibrosis which is consistent with our data, but nobody thought about cystic fibrosis or about idiopathic pulmonary fibrosis as diseases of senescence: they thought it was preventing the formation of the myofibroblasts, but we believe it was killing the myofibroblasts, which are now known to be senescent cells.

The reason you want to get rid of the senescent cells is because they are actually contagious. They secrete IL-6, which is an inflammatory mediator; and they make other cells senescent by diffusion of the inflammatory mediators, which explains why as you get older you accumulate more and more senescent cells. By the time youre 40 or 50 years old, you have aches and pains and you feel stiffness: these are a symptom that you are beginning to accumulate senescent cells.

All of this is very reminiscent of what happens in patients with COVID-19. Fatality rates are much higher in older patients and in patients with ageing-associated diseases, such as diabetes or coronary artery disease. IL-6 levels have been shown to be the best predictor for whether or not a patient will to wind up on a respirator and these patients may die from inflammation in the lung and the resulting fibrosis. It all sounds similar to a very acute episode of either cystic fibrosis or of idiopathic pulmonary fibrosis.

The virus has something called a host receptor, which allows the virus to bind the surface of the cells and then get internalised. For COVID-19, there are two proposed host receptors: one is CD-26, which is a marker of senescence; and the other one is ACE-2, which is also increased during senescence. This would suggest that the virus is preferentially targeting cells with markers of senescence.

We think of senescent cells as old and not very energetic, but they have to secrete a lot of inflammatory mediators, like IL-6, so they actually have very active protein metabolism and they do a lot of protein synthesis IL-6 is a protein and they produce inflammatory mediators of the senescence associated secretory phenotype (SASP). Therefore, the virus would want to invade a cell that is better at protein synthesis in order to make more copies of itself and the necessary viral spiked glycoproteins, to package the viral RNA or DNA for viral replication. This virus is seeking out the cells that are the best at making protein, to make more copies of itself, so it gets in the cell and takes over.

The predilection for fatalities in patients with advanced chronological age suggests there is a connection with senescence; and azithromycin, which appears to be working in clinical trials, is a senolytic and an antifibrotic. Certain antibiotics of the azithromycin class of which there are many are inhibitors of protein synthesis. The same is true of tetracyclines like doxycycline. These drugs would inhibit protein synthesis, so they would block IL-6 production and also block viral replication. Azithromycin has been shown to inhibit Zika virus and Ebola virus replication; and doxycycline has been shown to inhibit Dengue virus replication. Any drug which is a protein synthesis inhibitor, like certain classes of antibiotics, would also inhibit viral replication not because of any characteristics specific to the virus, but because its inhibiting protein synthesis, which is required for their viral replication.

The question, then, is why we cant use these drugs now in the clinic. In the United States, if a drug is prescribed off-label, its perfectly legal: the FDA approves a drug after Phase 1, Phase 2 and Phase 3 clinical trials for a particular indication. Then because the drug already went through Phase 1, which is a safety trial, it can be legally prescribed for any other disease indication off-label. The FDA will not actually have to directly approve doxycycline or azithromycin for treatment of COVID-19, because doctors can already prescribe it.

In a time of crisis, we need to practise what people are calling battlefield medicine, where we think outside the box. Theres already evidence in the published literature that these antibiotics have the protein synthesis inhibition side effect and have already been shown to inhibit viral replication. The problem in this country is people are rightfully afraid of antibiotic resistance. Its the kind of thing that has been ingrained in the mindset of doctors in the UK. However, I think we need to rethink the whole use of antibiotics to target viral infections. In fact, if you look in the literature for herpes virus (HSV), its already been shown that erythromycin, which is another protein synthesis inhibitor, is used either orally or as a cream to treat herpes outbreaks.

If we could give NHS workers either doxycycline or azithromycin prophylactically, the viral load would likely be gone or severely diminished. This would prevent the spread of the virus from one person to another, protecting clinicians against people who come to the hospital; and could also be used to treat patients. But, I think the key here is to avoid the fibrosis and the inflammation, which starts with the fever. When a patient comes down with a fever, they should immediately give them the doxycycline or the azithromycin, which will shut down IL-6 production and shut down the viral replication; so the patient is less likely to transmit the disease to healthcare workers.

All these drugs are very inexpensive the cost of doxycycline is 10 pence a day; azithromycin is also very cheap, because it came off patent in 2017 so these drugs could be used for prophylaxis and for treatment. Then potentially we could relax some of the social distancing and we could all go back to work. The problem is were not going to have vaccines for another 12 to 24 months, so we need something now thats already safe, thats MHRA- or FDA-approved for at least one indication. It may be something that can be used in conjunction with social distancing: some people dont have extra space in their house where they can really isolate, so then they could take an antibiotic like doxycycline or azithromycin to reduce viral loads. This would reduce the stress on the healthcare system, because if you treat people in the early stages and it works, they wont get to the ventilator stage and the problem is when you get to the ventilator stage, the patients lungs have effectively turned to cement from all the fibrosis, so the chances of getting people off the ventilator is rather low. Its very serious once you get to the ICU, so you want to prevent the onset of respiratory symptoms, by treating patients as soon as possible with an antibiotic that will shut down viral replication.

Doxycycline is the number one drug prescribed worldwide for any indication: its used for malaria, its mainly used for acne; and people will take it for six months at a time without any real issues, except maybe some stomach upset. People with acne rosacea take it for their whole life, especially in very disfiguring cases usually they recommend a drug holiday for a week or two, every six months. Doxycycline was approved first in 1967. Its not a senolytic, but it does inhibit IL-6 and it inhibits viral replication; and it has been shown by other people to be an anti-ageing drug as well. Both of these drugs are very cheap; and they should be in abundant supply worldwide.

SARS-CoV-1, the precursor for COVID-19, shows the same pattern of infection. They conducted experiments in humans and mice and saw that, for example, young mice will become infected, but it doesnt cause any real disease there is no inflammation or fibrosis; and a very mild pneumonia but if they use older mice aged 12 to 14 months, they see very severe inflammation, fibrosis and death. This is due to the induction of a very strong inflammatory response, which includes the IL-6. This original mouse model could be used to test this hypothesis regarding senolytics, but as these drugs are already FDA-approved, we can do that in parallel. The problem is its a question of time; and the longer we wait, the more people are infected, when we could just shut it down now. We could use patients already in hospital, you would have instant clinical trials. This is battlefield medicine. We should take advantage of the patient population with drugs that have very few side effects, and conduct clinical trials on a large scale.

I think people are in a state of helplessness. They dont know what to do, and the solution could be right under our noses. What were doing is not working, for many patients, and we need to change something; and the first step would be propagate the idea of field clinical trials. We can record all the data from the treatment of the patients as it progresses thousands of people have the disease and it could be a multicentre trial, the most important thing is to get something going now.

Much research into the treatment of COVID-19 is currently focused on the drugs chloroquine and azithromycin; and the FDA has granted an emergency licence for the use of chloroquine to treat COVID-19 patients. The European Medicines Agency has not yet followed suit, asserting that more research should be conducted; and some researchers have highlighted concerns over toxicity issues associated with chloroquine and its derivative, hydroxychloroquine.

Patients who are prescribed chloroquine or hydroxychloroquine normally would have to take a test for a glucose-6-phosphate dehydrogenase deficiency (G6PD) [an hereditary condition which increases the risk of haemolysis when chloroquine is administered]; and there are other issues with both chloroquine and hydroxychloroquine. I think the side effects may outweigh the benefits, because its not an inhibitor of viral replication; its an inhibitor of viral entry. If the patient is already sick, they already had the viral entry, then chloroquine will not necessarily shut down the viral replication. It only works for patients who have not already been infected.

In the clinical data from the French trial of hydroxychloroquine and azithromycin, the chloroquine did relatively little by itself and that has been called into question in terms of the effects. The combination with azithromycin was much more effective, but they didnt test azithromycin alone, which would probably be sufficient; because even if viral entry does occur, as long as the viral replication is inhibited, the virus will not propagate. We believe that the hydroxychloroquine isnt necessary; and we can reduce the risk to older patients by eliminating the hydroxychloroquine.

Azithromycin has some very mild side effects, but theyre not very prevalent; if they had been prevalent the drug would have been pulled off the market. There was some controversy as to the reproducibility of the studies regarding its side effects: multiple studies were done and some are positive, some are negative, so theres still a warning out there but the side effects only really occur with high doses of azithromycin, which would not be needed in this case. If azithromycin did cause problems for a patient they could switch to doxycycline, or they could start with doxycycline in the first place. These are just two examples of classes of drugs; there are other drugs which inhibit protein synthesis: erythromycin is in the same class as azithromycin, and it inhibits protein synthesis. It doesnt have the senolytic activity, but it would still inhibit the IL-6 and the viral replication.

The same is the case for the tetracyclines these are classes of drugs which are relatively similar and interchangeable, so if we run out of doxycycline, we would still have minocycline, tetracycline and all these other variations which have a similar effect on protein synthesis. The main issue with doxycycline is patients can experience some stomach upset or some nausea, but this can be alleviated by using a probiotic.

That would be the primary role of these drugs. Based on the results of clinical trials, the NHS could implement its usage. For example, ICU staff could receive it first, as they are in contact with patients that pose the most severe risk. Hospital staff right now are probably terrified of catching it, so why not take a prophylactic antibiotic, which has a chance of preventing infection? Im sure theyre doing a great job taking care of the patients, but it is traumatic to be under all this stress constantly. Its very stressful to be in such a high pressure situation, where youre afraid for your own life, but youre also trying to help other people at the same time. Then, you have your family at home and you dont want to also make them sick either. Healthcare workers are the people who are at the greatest risk; and already weve seen a reduction in NHS staff levels around one in four NHS staff are not at work, because they have either been infected or are isolating because they have symptoms.

We dont want to lose too many of the doctors and nurses in this crisis, so this would be helpful for everyone especially for preventing the further spread to shut down viral replication and contagion. Anything that can be done to reduce the viral load will reduce the contagion. They can do trials with young healthy volunteers who are asymptomatic, but it would be better to do it with the NHS staff who would need it most as a preventative approach for prophylaxis. We have recently proposed and published this prophylaxis strategy in a Letter to the Editor at the British Medical Journal (BMJ), which is widely read by GPs and consultants in the UK.

1 Letter to the Editor, British Medical Journal: https://www.bmj.com/content/368/bmj.m1252/rr-20

2 Lisanti, Sotgia et al. (2020). Senescence, ageing and potential COVID-19 treatments. Aging-US. https://www.aging-us.com/article/103001/text

Professor Michael P Lisanti, MD-PhD, FRSA, FRSBChair in Translational MedicineSchool of Science, Engineering & EnvironmentUniversity of Salford+44 (0)1612 950 240M.P.Lisanti@salford.ac.uk

This article is from issue 13 of Health Europa. Clickhere to get your free subscription today.

Follow this link:
Could these senolytic drugs halt the spread of COVID-19? - Health Europa

Doctors revealed details of the new rescue of Michael Schumacher – The Times Hub

Legendary German racing driver expects to implement the next batch of stem cells into heart tissue

Sevenfold champion of Formula 1 Michael Schumacher will have to go through another operation, according to GrandPX with reference to the Italian source Contro Copertina. As noted cardiac surgeon, Dr. Phillip Menashe, who was already engaged in treatment of the legendary German racer earlier, Schumacher will conduct the experimental operation on the introduction of stem cells into heart tissue.

Last year it was reported that Michael has already passed a similar procedure. The goal is to restore the nervous system Michael, said Menashe.

Neurosurgeon Dr. Nikola Acciari told that a famous former pilot Ferrari also suffers from muscle atrophy and osteoporosis. Over the last 20 years science has made enormous progress in the field of stem cell treatment. But it doesnt change the fact that we still know little about the human brain. We cant tell what results it will bring, said the doctor.

Michael Schumacher. Photo skysports.com

Recall Michael Schumacher suffered a severe head injury in December 2013 in the result of a fall at a ski resort in France. Since then Schumacher, who in January turned 51, never appeared in public.

About the state of his health there is no reliable information because the family prefers to keep it a secret. However, last fall it became known that Michael Schumacher is secretly transported to a clinic in Paris. In this case an unnamed member of the medical personnel told reporters: He is conscious.

Subscribe to our telegram

Only the most important and interesting

Subscribe

More:
Doctors revealed details of the new rescue of Michael Schumacher - The Times Hub